ClinicalTrials.gg
CompletedNCT01424449Updated Dec 17, 2012

A PET Study in Healthy Volunteers

A Phase 1 interventional study of [11C]PHNO and Aripiprazole in Depressive Disorder, sponsored by GlaxoSmithKline. Completed at 1 site in United Kingdom. Open to male participants aged 22 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-12-17.

Sponsored by GlaxoSmithKline · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
22 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies in Depressive Disorder by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Depressive Disorder · GlaxoSmithKline.

Enrollment
33rd of 35
7 · median 33
Started
2010
with 1 other
Phase 1
25 of 39
none open now
Registered
37th of 39
by date

Among the 39 studies in Depressive Disorder by GlaxoSmithKline, this one is the 33rd largest by enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2010, is one of 25 in phase 1, and was the 37th registered.

Depressive Disorder

855 studies on the registry are indexed under Depressive Disorder; 159 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

None of the 39 studies in Depressive Disorder by GlaxoSmithKline is open now. The open studies under Depressive Disorder, anywhere →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 22 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies in Depressive Disorder by GlaxoSmithKline as a file.
02

Study summary

This will be an open label, non-randomised [11C]PHNO PET study using healthy male volunteers. Each volunteer will undergo 4 [11C]PHNO PET scans to allow for further characterisation of this radioligand and examine the effects of [11C]PHNO mass carry-over and displaceable binding in the brain. This study aims to obtain data from 6 evaluable subjects.

Read the detailed description

A test-retest (TRT) investigation of [11C]PHNO in human is required to further characterise [11C]PHNO. [11C] PHNO possesses very high affinity for the D3 receptor, and therefore most clinical studies are conducted at D3 occupancies >10%. As [11C]PHNO kinetics in the target brain regions are moderately slow, considerable mass carry over may be present on a 2nd PET scan conducted on the same day. In addition there appears to be a significant displaceable binding component in the cerebellum, which, if not accounted for, will lead to a bias in the quantification of specific [11C]PHNO binding. The aim of this study is therefore to examine the effects of [11C]PHNO mass carry-over and displaceable binding in the cerebellum, on the quantification of [11C]PHNO PET data.

This will be an open label, non-randomised [11C]PHNO PET study using healthy volunteers. Each volunteer will undergo 4 [11C]PHNO PET scans:

1st and 2nd scans; TRT on the same day with a minimal gap between [11C]PHNO injections to examine the effects of PHNO mass carry over, 3rd scan >1 week later to determine the "true" TRT variability and a 4th scan will follow a 15mg dose of aripiprazole (a D2/D3 compound which allows the highest clinically acceptable blockade of central D2/D3 receptors) and will examine the amount of displaceable binding in the cerebellum, a proposed reference tissue for [11C]PHNO.

The scan data will be quantified as regional volumes of distribution (VT).

03

Conditions studied

  • Depressive Disorder

Browse trials for

04

Who can participate

Ages eligible
22 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy as determined by a responsible physician
  2. Male subjects between 25 and 55 years of age.
  3. Male subjects must agree to use one of the methods listed
  4. Capable of giving written

Exclusion criteria

Exclusion Criteria:

  1. The subject has a positive pre-study drug/alcohol screen
  2. The subjects is using or has used regular prescription or non-prescription drugs
  3. Current or recent (within one year) gastrointestinal disease
  4. A screening with a value of >450msec and/or a PR interval outside the range 120 to 200msec or an ECG that is not suitable for QT measurements
  5. Pulse rate \<50 or >100 bpm OR a systolic blood pressure >140 or \<100 OR a diastolic blood pressure >90 or \<60.
  6. History of long QT syndrome (personal or family) or other cardiac conduction disorder, or other cardiac disease.
  7. Any previous or current psychiatric diagnosis listed in Axis I or II
  8. Any history of suicidal attempts, suicidal ideation or behaviour as assessed by appropriately trained study personnel.
  9. History of alcohol dependence
  10. The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  11. Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  12. History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  13. Where participation in the study would result in donation of blood or blood products in excess of 550 mL within a 56 day period.
  14. Previous inclusion in a research and/or medical protocol involving nuclear medicine, PET or radiological investigations with significant radiation burden
  15. Family history of cancer
  16. History of claustrophobia or subjects feeling that he will be unable to lie still on his back in the PET camera for a period of \~2 hours at a time.
  17. History or presence of a neurological diagnosis
  18. Presence of a cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies as assessed by a standard pre-MRI questionnaire.
  19. Unwillingness or inability to follow the procedures outlined in the protocol. -
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    no treatment

    Aripiprazole is a D2/D3 antagonist registered in the UK for use in the treatment of schizophrenia. It allows the highest clinically acceptable blockade of central D2/D3 receptors and will allow us to examine the amount of displaceable binding in the brain - a proposed reference tissue for \[11C\]PHNO.

    Radiation: [11C]PHNO · Drug: Aripiprazole

Interventions

  • Radiation[11C]PHNO

    examine the effects of \[11C\]PHNO mass carry-over and displaceable binding

  • A 4th scan will follow a 15mg dose of aripiprazole (a D2/D3 compound which allows the highest clinically acceptable blockade of central D2/D3 receptors)

06

What researchers measure

Primary outcomes

  1. volume of distribution

    Regional volume of distribution (VT) in sub-cortical, brainstem and cerebellar regions of interest at each PET scan.

    Time frame: one year

07

Study locations

1 site
  • GSK Investigational Site
    London, W12 ONN, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2011
First posted
Aug 29, 2011
Start
Jan 2010
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Last update
Dec 17, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01424449
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 29, 2011
Start date
Jan 2010
Primary completion
Jul 2010
Completion
Jul 2010
Last update
Dec 17, 2012

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion